Companies / Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc.
STSACIK 1692830
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 6, 2023 | Takanashi Ken Director | Buy Open-market buy | Common Stock, $0.0001 par value | $20.07M | +22.1M +789.29% | 24,847,694 | high |
| Jun 8, 2023 | Shin Nippon Biomedical Laboratories, Ltd. 10% owner | Buy Open-market buy | Common Stock | $7.67M | +8.4M | 8,423,732 | high |
| Feb 26, 2021 | Ra Capital Management, LLC Director | Buy Open-market buy | Common Stock | $7.00M | +1.2M +31.41% | 5,155,854 | high |
| Jun 6, 2023 | Shah Rajeev M. Director | Other Shares tendered | Common Stock, $0.0001 par value | $5.38M | -5.9M -100.00% | 0 | low |
| Nov 14, 2022 | Leonard Braden Michael 10% owner | Buy Open-market buy | Common Stock | $3.87M | +5.6M | 5,608,306 | high |
| Apr 1, 2021 | Ra Capital Management, LLC Director | Other Other (per filing) | Common Stock | $3.35M | +566K | 566,011 | low |
| Nov 14, 2022 | Commodore Capital LP 10% owner | Sell Open-market sale | Common Stock, par value $0.0001 per share | $2.29M | -3.3M -87.57% | 461,286 | medium |
| Apr 1, 2021 | Ra Capital Management, LLC Director | Other Other (per filing) | Common Stock | $1.14M | +192K +3.73% | 5,348,241 | low |